1. Home
  2. KALA vs NTWK Comparison

KALA vs NTWK Comparison

Compare KALA & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • NTWK
  • Stock Information
  • Founded
  • KALA 2009
  • NTWK 1997
  • Country
  • KALA United States
  • NTWK United States
  • Employees
  • KALA N/A
  • NTWK N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • NTWK Computer Software: Prepackaged Software
  • Sector
  • KALA Health Care
  • NTWK Technology
  • Exchange
  • KALA Nasdaq
  • NTWK Nasdaq
  • Market Cap
  • KALA 26.2M
  • NTWK 56.1M
  • IPO Year
  • KALA 2017
  • NTWK 1998
  • Fundamental
  • Price
  • KALA $0.96
  • NTWK $4.56
  • Analyst Decision
  • KALA Buy
  • NTWK
  • Analyst Count
  • KALA 3
  • NTWK 0
  • Target Price
  • KALA $31.50
  • NTWK N/A
  • AVG Volume (30 Days)
  • KALA 2.7M
  • NTWK 116.0K
  • Earning Date
  • KALA 11-11-2025
  • NTWK 11-12-2025
  • Dividend Yield
  • KALA N/A
  • NTWK N/A
  • EPS Growth
  • KALA N/A
  • NTWK 316.67
  • EPS
  • KALA N/A
  • NTWK 0.25
  • Revenue
  • KALA N/A
  • NTWK $66,088,229.00
  • Revenue This Year
  • KALA N/A
  • NTWK N/A
  • Revenue Next Year
  • KALA N/A
  • NTWK N/A
  • P/E Ratio
  • KALA N/A
  • NTWK $18.00
  • Revenue Growth
  • KALA N/A
  • NTWK 7.65
  • 52 Week Low
  • KALA $1.10
  • NTWK $2.14
  • 52 Week High
  • KALA $20.60
  • NTWK $5.75
  • Technical
  • Relative Strength Index (RSI)
  • KALA 26.61
  • NTWK 49.31
  • Support Level
  • KALA $1.36
  • NTWK $4.45
  • Resistance Level
  • KALA $1.52
  • NTWK $4.63
  • Average True Range (ATR)
  • KALA 0.14
  • NTWK 0.24
  • MACD
  • KALA -0.10
  • NTWK -0.04
  • Stochastic Oscillator
  • KALA 16.67
  • NTWK 27.27

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About NTWK NetSol Technologies Inc. Common Stock

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

Share on Social Networks: